Alzheimer’s Inhibitor BACE to Enter Worldwide Phase 2/3 Trial

Alzheimer’s Inhibitor BACE to Enter Worldwide Phase 2/3 Trial
Alzheimer's Therapeutic Research Institute (ATRI) at the University of Southern California, and Janssen Research & Development will collaborate for a  Phase 2/3 clinical trial of Jansen’s BACE blocker intended to delay or even prevent Alzheimer’s symptoms. The BACE blocker is a drug that prevents the action of an enzyme involved in the production main cause of plaque build-ups in the brains of Alzheimer’s patients - amyloid-β protein. People who currently show no Alzheimer’s symptoms but are older than age 60 and have an accumulation of amyloid-β in their brains, wil
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *